Skip to main content
 

Dimiter S. Dimitrov, Ph.D.

Senior Investigator
Laboratory of Experimental Immunology
NCI/CCR
Building 567, Room 152
P.O. Box B
Frederick MD, 21702-1201
301-846-1352

Research Topics

Protein Interactions

Protein interactions are important for understanding of biological function, and for prevention, diagnosis and treatment of diseases. Our research focuses on antibody-antigen and ligand-receptor interactions. We identify novel human monoclonal antibodies, characterize and improve their properties, elucidate their mechanisms of interactions, investigate antibody-mediated modulation of ligand-receptor interactions, and apply the knowledge gained to solve biomedical problems. Our major long-term goal is to develop antibody-based therapeutics including engineered antibody domains and antibody-guided nanoparticles against cancer and other diseases. Currently, we identify, engineer and characterize antibodies against components of the insulin-like growth factor (IGF) system and other cancer-related proteins, HIV, and emerging and biodefense-related microbes including Nipah and Hendra viruses, and dengue virus. We also study mechanisms of antibody elicitation and proposed a new (germline/maturation) concept with implications for development of vaccines against AIDS and other diseases.

Biography

Dr. Dimitrov obtained his Ph.D. in chemistry at the University of Sofia, and his Sc.D. in biology at the Bulgarian Academy of Sciences, where he was elected as a Professor of Biophysics. He was appointed to the Senior Biomedical Research Service at NIH and selected as an NCI outstanding mentor. His research focuses on development of human monoclonal antibodies including isolated engineered antibody domains for prevention and treatment of cancer and other diseases.

Selected Publications

  1. Chen W, Gong R, Ying T, Prabakaran P, Zhu Z, Feng Y, Dimitrov DS. Discovery of novel candidate therapeutics and diagnostics based on engineered human antibody domains. Curr Drug Discov Technol. 2014;11(1):28-40.
  2. Chen W, Feng Y, Prabakaran P, Ying T, Wang Y, Sun J, Macedo CD, Zhu Z, He Y, Polonis VR, Dimitrov DS. Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains. J Virol. 2014;88(2):1125-39.
  3. Sun JY, Shen J, Thibodeaux J, Huang G, Wang Y, Gao J, Low PS, Dimitrov DS, Sumer BD. In vivo optical imaging of folate receptor-β in head and neck squamous cell carcinoma. Laryngoscope. 2014;124(8):E312-9.
  4. Ofek G, Zirkle B, Yang Y, Zhu Z, McKee K, Zhang B, Chuang GY, Georgiev IS, O'Dell S, Doria-Rose N, Mascola JR, Dimitrov DS, Kwong PD. Structural basis for HIV-1 neutralization by 2F5-like antibodies m66 and m66.6. J Virol. 2014;88(5):2426-41.
  5. Tang Z, Feng M, Gao W, Phung Y, Chen W, Chaudhary A, St Croix B, Qian M, Dimitrov DS, Ho M. A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface. Mol Cancer Ther. 2013;12(4):416-26.
This page was last updated on May 21st, 2014